Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426359 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
A Phase 2 study, sponsored by Qurient Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT02426359: Completed Phase 2 study, sponsored by Qurient Co..
NCT02426359 is a Phase 2 study that has completed, run by Qurient Co.. The registered enrollment target is 57 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02426359, a Phase 2 study, has completed, sponsored by Qurient Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
Interventions
- DRUG Placebo
- DRUG Q301 Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
What the finished NCT02426359 record still lists
NCT02426359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02426359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02426359 about?
NCT02426359 is a clinical study titled "Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients". This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
What is the current status of trial NCT02426359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2015-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02426359?
The interventions under investigation include: Placebo (DRUG), Q301 Cream (DRUG).
Who is sponsoring clinical trial NCT02426359?
This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02426359's enrollment target sits among peer trials
57 1141st of 2000 higher than 855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia